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RESPONSE: We appreciate the comments of Drs. 
Kaye and Hill on our article. We are pleased that these 
investigators concurred with our impression that pho-
todynamic therapy (PDT) may potentially be useful in 
the treatment of posterior fossa tumors. Several inter-
esting questions were raised about the technical aspects 
of our method of determining tissue Photofrin levels 
in tumor and surrounding normal brain. Our laboratory 
concurs with their feelings about the limitations of rela-
tive fluorescence. We have therefore conducted addi-
tional investigations with radiolabeled Photofrin to 
quantify tissue levels by yet another technique. 
The biodistribution of 111In-Photofrin was deter-
mined in animals with brain tumors from the same ca-
nine glioma cell line used in the currently published 
studies. The tumor to non tumor ratio ranged between 
6.45 and 7.16, at times ranging from 24 to 72 hours 
after injections. Radioactivity in brain and tumor tissue 
was detected using a Packard multisample auto gamma 
counter (Cobra) with five gamma detectors. It is also 
of note that our ratios of target to nontarget (tumor to 
nontumor brain) Photofrin uptake agree with the pub-
lished results of Origitano, et al} in which patients 
with glioblastoma demonstrated target to nontarget ra-
tios of Photofrin uptake ranging from 2.5 to lOA. We 
feel that our subsequent animal model studies and the 
published patient data of Origitano, et ai., confirm our 
previously published data on Photofrin uptake in the 
presently quoted preclinical study. 
We believe that Drs. Kaye and Hill make an appro-
priate point about assessing possible thermal effects of 
laser irradiation using the treatment protocol we de-
scribed in the current study. We, too, shared this con-
cern during our experiments and placed intra tumor 
temperature thermistors during each laser irradiation 
session adjacent to the spherical diffusion tip of the 
fiberoptic catheter. In no situation was there a signifi-
cant temperature rise recorded by this thermal probe. 
We were not satisfied, however, because of our concern 
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over tissue heating. We therefore conducted additional 
studies in which we used laser-only controls in com-
parison to PDT in order to document possible thermal 
effects from the laser point source. In such controls, 
a small defect was revealed on magnetic resonance im-
aging (pathologically/histologically confirmed) at the 
tip of the fiberoptic catheters, which was possibly due 
to thermal effects not demonstrated using our tempera-
ture probe. We have subsequently carried out additional 
experiments in dogs using even lower doses of laser 
light and the balloon adapter technique described by 
Muller and Wilson! to provide between 33 and 100 J/sq 
cm. We have succeeded in treating residual malignant 
brain tumor tissue directly adjacent to the brain stem 
with markedly reduced neurotoxicity if the lower light 
dose and the lower (0.75 mg/kg) Photofrin dose was 
utilized. Survivable brain-stem toxicity (resolving 
hemiparesis) occurred with this technique in a dog so 
treated. 
Our model using a canine glioma cell line in the pos-
terior fossa location and a single fiber laser irradiation 
technique was not intended to convince readers that this 
is the best method of future treatment for human pos-
terior fossa brain tumors using PDT. Our model was 
intended to be more scientifically rigorous, treating 
brain tumors with only one therapeutic modality, thus 
not combining the results of surgical resection with 
those of photodynamic effect. We therefore feel that 
our ability to treat posterior fossa brain tumors near the 
brain stem with a technique such as ours, which does 
not minimize the possible cerebral edema or tumor bur-
den by prior surgical resection, constitutes a worst-case 
scenario. Therefore, any survivability in our animal 
model with objective evidence of a therapeutic re-
sponse constitutes an intellectually honest assessment 
of the PDT regimen, without confounding variables. 
Use of resection, balloon techniques with intracavitary 
irradiation, or multiple fiber techniques, among others 
may certainly improve upon therapeutic efficacy and 
control of neurotoxicity in human clinical applications. 
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